The Clotrimazole Market size is estimated to reach $3.7 billion by 2027 and it is poised to grow at a CAGR of 6.2% over the forecast period of 2022-2027. Clotrimazole
belongs to the chemical family of azole derivatives and was primarily invented
as an antifungal cream. Due to the drug’s unremarkable side effects and
uncomplicated metabolic profile, the drug gained traction across the globe for
treatments pertinent to mycotic outbreaks such as vaginal yeast infections, athlete’s
foot and otomycosis. Moreover, Lotrimin AF Antifungal Cream along with other
clotrimazole agents belongs on the essential medicine list. Due to the following reasons, the Clotrimazole industry is positioned favorably during the forecast
period of 2022-2027.
Clotrimazole Market Drivers
As per CDC estimates, the prevalence of vaginitis is extremely high in ethnic groups of African-Americans when compared to the white population. Moreover, the population of African-Americans has been on the rise which would proliferate the demand for the product. As per Census.Gov, the black population stood at 46.80 million or 12.4% of all living, as compared to 38.9 million in 2010. Additionally, the cases of tinea pedis have been increasing on the global level.
For More Queries About "Clotrimazole Market" @ https://www.industryarc.com/support.php?id=17881
Clotrimazole has been largely revered as a therapeutic in cancer treatment. The mechanism of action is based on the inhibition of mitochondrial-bound glycolytic enzymes and calmodulin, which starves cancer cells of energy. As per Cancer.Org 2021, the estimated number of new cancer cases within the U.S. would be equivalent to 1.9 million. Furthermore, clotrimazole finds extreme utility in cases of dermatitis. The worldwide prevalence of seborrheic dermatitis is around 5%.
Research and Product Launch
In May 2022, Bayer relaunched its products based on Clotrimazole in India under the improved version known as Canesten. The available format for the product has been powder and cream.
In March 2022, Research provided for the higher efficacy of Clotrimazole to inhibit HCC Migration and Invasion by Modulating the ERK-p65 signaling pathway. Hepatocellular carcinoma (HCC) has a very high mortality rate and is the most common type of liver cancer. Clotrimazole, a traditional antifungal drug, has garnered considerable attention as a therapeutic strategy for HCC.
The Major Players in the Market
The notable players in the market include Bayer, Walgreens, F.I.S., Corden Pharma, INFA Group, Manus Akkteva, Amoli Organics, Glenmark Pharmaceuticals, Mosaic Wellness Private Limited, FDC Limited and Cipla Ltd.
Over the years, major market players have focused on incorporating product formulations on the need by advancing certain compositions. Furthermore, start-ups are entering the OTC segment to leverage the growing market and utilize their already established brand presence on third-party websites and other platforms. The growing population proliferated by different product forms would help the Clotrimazole market during the forecast period of 2022-2027.
Mr. Venkat Reddy
Email: [email protected]
Contact Sales: +1-970-236-3677